• Corpus ID: 42543670

Heme Iron Polypeptide (Proferrin®) versus Oral and Injectable Iron Products for the Treatment of Anemia

  title={Heme Iron Polypeptide (Proferrin{\textregistered}) versus Oral and Injectable Iron Products for the Treatment of Anemia},
  • Published 2007
  • Medicine, Political Science
Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it… 
1 Citations

Tables from this paper

Heme iron polypeptide in treatment of anemia inpregnancy
Heme Iron Polypeptide is a better source of iron for iron deficiency anemia in pregnancy, as it has less side effects especially gastrointestinal side effects, because of which it has better compliance.


Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
  • A. Nissenson, J. Berns, P. Seligman
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2003
Effective utilization of erythropoietin with intravenous iron therapy
Intravenous iron therapy is a safe and cost‐effective method for maintaining or improving Hb levels with a more effective utilization of EPO in patients with low SF levels despite oral iron therapy.
Clinical studies of hip: An oral heme-iron product
A randomized controlled study of iron supplementation in patients treated with erythropoietin.
The results of this study suggest that, even in iron-replete patients, those supplemented with i.v. iron have an enhanced hemoglobin response to EPO with better maintenance of iron stores and lower dosage requirements of EPO, compared with those patients receiving oral iron and no iron supplementation.
Correction of Uremic Iron Deficiency Anemia in Hemodialyzed Patients: A Prospective Study
Evidence supports both the concept that iron absorption is compromised in chronic uremics and that the parenteral way is the more effective route for iron replacement in this specific group of patients.
Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis
Iron sucrose, given weekly as 200 mg IV push over 5 min is an effective and safe anemia treatment in this population of CKD patients, whereas those treated with oral iron had increases in hemoglobin without increases in iron stores.
A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
  • J. Stoves, H. Inglis, C. Newstead
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2001
In pre-dialysis patients, the efficacy of monthly 300 mg iron sucrose given intravenously is not superior with regard to haemoglobin response and rHuEpo dose as compared with a daily oral dose of 600 mg of ferrous sulphate or equivalent, and lower doses may help to reduce the incidence of allergic or "free iron" reactions.
Parenteral iron therapy options
The increased availability of multiple parenteral iron preparations should decrease the need to use red cell transfusions in patients with iron‐deficiency anemia.
Iron and cardiac disease in the end-stage renal disease setting.
  • A. Besarab
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1999
Several studies suggest that achievement of target hematocrit levels in ESRD patients improves several clinical outcomes and that anemia itself is a risk factor for cardiac disease.
Maintenance intravenous iron therapy in pediatric hemodialysis patients
It is suggested that maintenance IV iron is a more-economic method of iron supplementation for pediatric hemodialysis patients because it reduced the dose of EPO required to maintain blood hemoglobin levels.